MacroGenics Company Profile (NASDAQ:MGNX)

About MacroGenics

MacroGenics logoMacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MGNX
  • CUSIP:
Key Metrics:
  • Previous Close: $19.46
  • 50 Day Moving Average: $19.36
  • 200 Day Moving Average: $25.09
  • 52-Week Range: $34,835,000.00 - $14.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.78
  • P/E Growth: 0.04
  • Market Cap: $682.77M
  • Outstanding Shares: 34,835,000
  • Beta: 2.8
  • Net Margins: -55.01%
  • Return on Equity: -16.99%
  • Return on Assets: -14.99%
  • Current Ratio: 14.34%
  • Quick Ratio: 14.34%
Additional Links:
Companies Related to MacroGenics:

Analyst Ratings

Consensus Ratings for MacroGenics (NASDAQ:MGNX) (?)
Ratings Breakdown: 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $34.83 (77.72% upside)

Analysts' Ratings History for MacroGenics (NASDAQ:MGNX)
DateFirmActionRatingPrice TargetDetails
1/25/2017Citigroup Inc.Lower Price TargetNeutral$32.00 -> $24.00View Rating Details
12/19/2016SunTrust Banks, Inc.Initiated CoverageBuy$30.00View Rating Details
11/16/2016Roth CapitalReiterated RatingBuyView Rating Details
11/7/2016BTIG ResearchReiterated RatingBuy$35.00View Rating Details
11/3/2016WedbushReiterated RatingOutperform$52.00View Rating Details
9/7/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details
6/30/2016Morgan StanleyReiterated RatingHoldView Rating Details
6/14/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyView Rating Details
5/19/2016Leerink SwannReiterated RatingOutperform$47.00View Rating Details
2/18/2016Janney Montgomery ScottInitiated CoverageBuy$36.00View Rating Details
8/6/2015Stifel NicolausReiterated RatingBuy$51.00 -> $56.00View Rating Details
(Data available from 2/26/2015 forward)


Earnings History for MacroGenics (NASDAQ:MGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($0.89)$10.65 millionN/AView Earnings Details
11/2/2016Q316($0.80)($0.97)$12.45 million$3.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.02)$1.12$27.22 million$80.67 millionViewN/AView Earnings Details
5/4/2016Q1($0.67)($0.88)ViewN/AView Earnings Details
2/29/2016Q4($0.60)($0.88)ViewListenView Earnings Details
8/3/2015Q2($0.44)($0.71)ViewN/AView Earnings Details
5/6/2015$0.87($0.58)ViewN/AView Earnings Details
3/3/2015($0.36)($0.69)ViewN/AView Earnings Details
11/11/2014($0.42)($0.14)ViewListenView Earnings Details
8/5/2014($0.29)($0.44)ViewN/AView Earnings Details
5/6/2014($0.09)($0.12)ViewN/AView Earnings Details
11/12/2013$0.15$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MacroGenics (NASDAQ:MGNX)
Current Year EPS Consensus Estimate: $-1.61 EPS
Next Year EPS Consensus Estimate: $-3.39 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.92)($0.46)($0.70)
Q2 20164($0.91)($0.48)($0.69)
Q3 20163($0.92)($0.77)($0.84)
Q4 20164($1.23)($0.67)($0.95)
Q1 20172($0.89)($0.72)($0.81)
Q2 20172($0.91)($0.75)($0.83)
Q3 20172($0.91)($0.77)($0.84)
Q4 20172($0.95)($0.80)($0.88)
(Data provided by Zacks Investment Research)


Dividend History for MacroGenics (NASDAQ:MGNX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for MacroGenics (NASDAQ:MGNX)
Insider Ownership Percentage: 6.78%
Institutional Ownership Percentage: 81.68%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2016Jon Marc WiggintonCMOSell10,000$29.34$293,400.00View SEC Filing  
10/3/2016Lynn CilinskiVPSell6,231$29.28$182,443.68View SEC Filing  
8/1/2016Jon Marc WiggintonSVPSell20,000$30.78$615,600.00View SEC Filing  
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.00View SEC Filing  
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.84View SEC Filing  
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.00View SEC Filing  
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.00View SEC Filing  
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.00View SEC Filing  
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.48View SEC Filing  
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.93View SEC Filing  
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for MacroGenics (NASDAQ:MGNX)
News IconShares in Review: MacroGenics, Inc. (NASDAQ:MGNX) - Searcy News (NASDAQ:MGNX) - February 24 at 7:45 PM
News IconLevels in Review on Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Midway Monitor (NASDAQ:MGNX) - February 24 at 7:45 PM
News IconInvestor Watch on Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Baldwin Journal (NASDAQ:MGNX) - February 23 at 7:19 AM
News IconConsensus Estimates on Earnings & Stock Price in Focus for MacroGenics, Inc. (NASDAQ:MGNX) Shares - Aiken Advocate (NASDAQ:MGNX) - February 22 at 8:23 AM
News IconLooking at the Numbers for MacroGenics, Inc. (NASDAQ:MGNX) - BVN (NASDAQ:MGNX) - February 21 at 6:22 PM
News IconCompany Levels in Review: MacroGenics, Inc. (NASDAQ:MGNX) - Benton Bulletin (NASDAQ:MGNX) - February 17 at 3:15 PM
News IconStock Focus: Looking at Levels for MacroGenics, Inc. (NASDAQ:MGNX) - Rives Journal (NASDAQ:MGNX) - February 17 at 3:15 PM
News IconWhat Does The Chart For MacroGenics, Inc. (MGNX) Tell Us Presently? - NY Stock News (NASDAQ:MGNX) - February 17 at 3:15 PM logoMacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call (NASDAQ:MGNX) - February 16 at 6:07 PM logoMacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference - GlobeNewswire (press release) (NASDAQ:MGNX) - February 10 at 12:40 AM logoMacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:MGNX) - February 9 at 7:32 PM
News IconMy Watchlist for Tuesday, February 07 (NASDAQ:MGNX) - February 6 at 6:37 PM logoMacroGenics, Inc. (NASDAQ:MGNX) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:MGNX) - February 4 at 6:31 PM
News IconSignal Watch: Checking the Numbers for Macrogenics Inc. (MGNX) - Market Point (NASDAQ:MGNX) - January 30 at 7:13 PM
News IconStock Focus: Watching RSI Levels on Shares of Macrogenics Inc. (MGNX) - Market Point (NASDAQ:MGNX) - January 26 at 9:27 PM logoMACROGENICS INC Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:MGNX) - January 26 at 9:27 PM
News IconStock Spotlight: Zooming in on Shares of MacroGenics, Inc. (NASDAQ:MGNX) - The Tribune (NASDAQ:MGNX) - January 25 at 7:58 PM logoMacroGenics Announces Appointments to Board of Directors - GlobeNewswire (press release) (NASDAQ:MGNX) - January 25 at 7:58 PM
News IconMarket Stir - Advanced Volatility Spotted on Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Wall Street Beacon (NASDAQ:MGNX) - January 24 at 7:15 PM
News IconUpside Alert: Delving into Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Prospect Journal (NASDAQ:MGNX) - January 23 at 6:50 PM
News IconTechnical Update on Shares of Macrogenics Inc. (MGNX) - Sherwood Daily (NASDAQ:MGNX) - January 19 at 12:04 AM
News IconMacroGenics Inc MGNX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:MGNX) - January 18 at 4:56 AM
News IconReady for an Upsurge? Analysts Chime in on MacroGenics, Inc. (NASDAQ:MGNX) - Prospect Journal (NASDAQ:MGNX) - January 17 at 11:49 AM
News IconWill The Needle Move For MacroGenics, Inc. (NASDAQ:MGNX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:MGNX) - January 17 at 11:49 AM logoMacroGenics, Inc. (NASDAQ:MGNX) EPS Estimate At $-0.9225 - (NASDAQ:MGNX) - January 16 at 8:03 AM logoMacroGenics (MGNX) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:MGNX) - January 13 at 7:51 PM logoD.C.-area biotech stocks fall on Trump's tough talk on industry (NASDAQ:MGNX) - January 12 at 12:08 AM logoMacroGenics, Inc. (NASDAQ:MGNX) Is Expected To Post EPS Of ... - (NASDAQ:MGNX) - January 8 at 6:17 PM
News IconStock in Focus: MacroGenics, Inc. (NASDAQ:MGNX) - Wall Street Beacon (NASDAQ:MGNX) - January 8 at 6:17 PM logoMacrogenics (MGNX) Granted FDA Orphan Drug Status for MGD006 to Treat AML (NASDAQ:MGNX) - January 5 at 7:58 PM logoMacroGenics to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:MGNX) - January 5 at 7:58 PM logoMacroGenics’ MGD006 Granted Orphan Drug Status for AML by FDA (NASDAQ:MGNX) - January 5 at 7:58 PM logo4:33 pm MacroGenics confirms that the FDA has granted orphan drug designation to MGD006 for the investigational treatment of acute myeloid leukemia - also known as S80880 - a DART molecule that recognizes both CD123 and CD3 (NASDAQ:MGNX) - January 5 at 7:58 PM logoMacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA (NASDAQ:MGNX) - January 5 at 7:58 PM logoMacroGenics, Inc. (NASDAQ:MGNX) EPS Estimaged At $-0.9225 - (NASDAQ:MGNX) - December 31 at 11:22 PM
News IconEquity in Focus: MacroGenics, Inc. (NASDAQ:MGNX) - Wall Street Beacon (NASDAQ:MGNX) - December 25 at 5:56 PM
News IconMF Rank Review for MacroGenics, Inc. (NASDAQ:MGNX) - Business Daily Leader (NASDAQ:MGNX) - December 21 at 9:04 AM
News IconRating Buzzer: Buy Rating Was Given to MacroGenics (NASDAQ:MGNX) By a Broker (NASDAQ:MGNX) - December 20 at 12:28 PM logoCoverage initiated on MacroGenics by SunTrust (NASDAQ:MGNX) - December 20 at 12:27 PM
News IconShares in View: MacroGenics, Inc. (NASDAQ:MGNX) - OIB News (NASDAQ:MGNX) - December 18 at 6:46 PM
News IconWhat The Charts Are Saying About MacroGenics, Inc. (NASDAQ:MGNX) - The Business Journal (NASDAQ:MGNX) - December 17 at 6:54 PM
News IconValue Score in View for MacroGenics, Inc. (NASDAQ:MGNX) - Business Daily Leader (NASDAQ:MGNX) - December 17 at 12:14 AM
News IconVC Score In Focus for MacroGenics, Inc. (NASDAQ:MGNX) - Marion Business Daily (NASDAQ:MGNX) - December 15 at 6:12 AM logoMacroGenics : Highlights Progress at 2016 R&D Day (NASDAQ:MGNX) - December 14 at 7:11 PM logoMacroGenics Highlights Progress at 2016 R&D Day (NASDAQ:MGNX) - December 13 at 6:56 PM logoMACROGENICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:MGNX) - December 13 at 6:56 PM logoMacroGenics Licenses Synthon's Technology to Develop an Anti-B7 ... - GlobeNewswire (press release) (NASDAQ:MGNX) - December 13 at 12:02 AM
News IconTrading Chatter: CCI and ADX Watch for Macrogenics Inc. (MGNX) - StockTalk Daily (NASDAQ:MGNX) - December 13 at 12:02 AM
News IconInvestors are Following Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Business Daily Leader (NASDAQ:MGNX) - December 13 at 12:02 AM logoMacroGenics Licenses Synthon’s Technology to Develop an Anti-B7-H3 ADC (NASDAQ:MGNX) - December 12 at 6:40 PM


What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Where is MacroGenics' stock going? Where will MacroGenics' stock price be in 2017?

9 analysts have issued 12 month price targets for MacroGenics' shares. Their forecasts range from $21.00 to $52.00. On average, they expect MacroGenics' stock price to reach $34.83 in the next year.

When will MacroGenics announce their earnings?

MacroGenics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns MacroGenics stock?

MacroGenics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Interwest Venture Management Co. (3.08%), State Street Corp (2.41%), Eventide Asset Management LLC (2.08%), Pinnacle Associates Ltd. (1.87%) and Franklin Resources Inc. (1.69%). Company insiders that own MacroGenics stock include Ezio Bonvini, Jon Marc Wigginton, Lynn Cilinski and Paulo F Costa.

Who sold MacroGenics stock? Who is selling MacroGenics stock?

MacroGenics' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Pinnacle Associates Ltd., Allianz Asset Management AG, Oxford Asset Management, Franklin Resources Inc. and Tudor Investment Corp Et Al. Company insiders that have sold MacroGenics stock in the last year include Jon Marc Wigginton and Lynn Cilinski.

Who bought MacroGenics stock? Who is buying MacroGenics stock?

MacroGenics' stock was acquired by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., FMR LLC, Marshall Wace LLP, Arrowstreet Capital Limited Partnership, First Light Asset Management LLC, Artal Group S.A., Opaleye Management Inc. and Two Sigma Investments LP.

How do I buy MacroGenics stock?

Shares of MacroGenics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of MacroGenics stock cost?

One share of MacroGenics stock can currently be purchased for approximately $19.60.

MacroGenics (NASDAQ:MGNX) Chart for Sunday, February, 26, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Earnings History Chart

Earnings by Quarter for MacroGenics (NASDAQ:MGNX)

Dividend History Chart

Dividend Payments by Quarter for MacroGenics (NASDAQ:MGNX)

Last Updated on 2/26/2017 by Staff